Orchid Pharma Ltd Share Price Today

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
Quant Small Cap Fund - Growth	34.66 Lac	34.66 Lac no change
UTI Value Fund - Regular Plan - Growth	13.08 Lac	12.00 Lac (8.28%)
Invesco India Contra Fund - Regular Plan - Growth	9.91 Lac	9.91 Lac no change
Kotak Multi Asset Allocation Fund - Regular Plan - Growth	9.43 Lac	9.43 Lac no change
Invesco India Smallcap Fund - Regular Plan - Growth	4.55 Lac	4.55 Lac no change

Saurabh Tyagi--Clovek,Advisory

24 Aug • 3:20 PM · SEBI-Registered Analyst

Orchid Pharma posted decent number in Q1 of the FY 27

ORCHPHARMA

announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: For Q1FY27, revenue from operations stood at Rs 30,417.13 lakh, registering a growth of 15.57% YoY compared to Rs 26,318.58 lakh in Q1FY26. On a QoQ basis, revenue decreased by 17.42% from Rs 36,832.71 lakh in Q4FY26. Total Income: The company reported a total income of Rs 30,599.97 lakh in Q1FY27, up 11.37% YoY from Rs 27,475.56 lakh in Q1FY26, but down 18.64% QoQ from Rs 37,610.08 lakh in Q4FY26. Net Profit: Net Profit for Q1FY27 was reported at Rs 322.44 lakh, showing a significant turnaround YoY from a Net Loss of Rs 569.22 lakh in Q1FY26. However, it saw an 87.52% decrease QoQ compared to Rs 2,583.94 lakh in Q4FY26. Total Comprehensive Income: Total comprehensive income for Q1FY27 was Rs 323.08 lakh, compared to a loss of Rs 584.70 lakh in Q1FY26 and a profit of Rs 2,714.21 lakh in Q4FY26.

DEEPAK PAL

17 Aug • 10:47 PM · SEBI-Registered Analyst

“Index पर दबाव हो सकता है, लेकिन अवसर खत्म नहीं होते—बस ध्यान सही Share और सही स्तरों पर होना चाहिए।”

आज का Market Outlook / Closing View Nifty: 24,287.65, -78 points (-0.32%) Sensex: 77,728, -281 points (-0.36%) Nifty ne 5th consecutive session decline diya. Main pressure elevated crude oil, Middle-East/U.S.-Iran tensions, IT selling aur FII outflow se aaya. 1. आज Nifty IT करीब 2% नीचे रहा।

INFY

Infosys, HCL Tech, TCS, Mphasis aur Persistent jaise stocks mein selling dekhi gayi. Global growth/demand concerns aur currency-related factors IT sentiment par pressure daal rahe hain. Focus: Infosys, TCS, HCL Tech, Mphasis, Persistent 2. Market weakness ke बावजूद Nifty Metal करीब 1.2% ऊपर रहा. Tata Steel करीब 1.47% चढ़ा, जबकि SAIL करीब 2.4% मजबूत रहा. Hindalco भी buying interest में रहा. इसके पीछे global metal prices और commodity-linked stocks में selective buying को देखा जा रहा है। Focus: Tata Steel, Hindalco, SAIL, JSW Steel, Jindal Steel 3. Overall market weak hone ke बावजूद Reliance Industries करीब 0.8% ऊपर बंद हुआ और ₹1,318 के आसपास रहा. इसलिए large-cap space में Reliance आज relative strength दिखाने वाले stocks में रहा. Focus: Reliance — अगर ₹1,320 के ऊपर strength sustain होती है तो technical momentum देखने लायक रहेगा. 4. HAL करीब 2.2% ऊपर रहा। Company ने Adani Defence और BEML के साथ manufacturing partnership agreement किया है, जिसने defence stocks में interest बढ़ाया. Focus: HAL, BEML, BEL, MIDHANI 5. Pharma में broad-based strength नहीं थी। Dr Reddy's करीब 2% गिरा, जबकि Orchid Pharma करीब 9.7% टूट गया, mainly regulatory/earnings-related concerns के कारण. दूसरी तरफ कुछ pharma names में buying भी दिखी. DRREDDY, SUNPHARMA, ORCHIDPHARMA 6. BSE — आज sharp correction BSE करीब 5% गिरा क्योंकि Jefferies ने stock को Hold से Underperform downgrade किया और target ₹3,520 से घटाकर ₹2,940 किया. Q1 results के बाद earnings estimates में भी कटौती की गई. इसलिए BSE में अभी fresh buying के बजाय risk/reaction देखना बेहतर रहेगा.

Sneha M Vasudeo

23 Jul • 2:33 PM · SEBI-Registered Analyst

Orchid Pharma: Stock Outlook

Orchid Pharma is a leading pharmaceutical company in India, specializing in the manufacture of active pharmaceutical ingredients (APIs) and generic formulations. It serves global markets with a focus on antibiotics, anti-inflammatory, and central nervous system therapies. Orchid Pharma has an operating revenue of Rs. 811.33 Cr. on a trailing 12-month basis. An annual revenue de-growth of -11% needs improvement, Pre-tax margin of 3% needs improvement, ROE of 1% is fair but needs improvement. The company has a reasonable debt to equity of 25%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 37% from 50DMA and 200DMA. Orchid Pharma is a prominent Indian pharmaceutical company known for manufacturing active pharmaceutical ingredients (APIs) and generic formulations. The company’s product portfolio includes antibiotics, anti-inflammatory drugs, and central nervous system (CNS) therapies, catering to both domestic and international markets. Orchid Pharma operates state-of-the-art manufacturing facilities that comply with global regulatory standards, including USFDA and EMEA, ensuring high-quality production. The company’s strong focus on R&D enables the development of innovative and cost-effective products, contributing to its competitive edge. With a commitment to quality, compliance, and customer satisfaction, Orchid Pharma plays a significant role in meeting global healthcare needs. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

AALGO BREATHS I SEBI RA

8 Jul • 11:50 AM · SEBI-Registered Analyst

Orchid Pharma Limited Latest Updates

ORCHPHARMA

$178 Million Exblifep Licensing Deal in Russia On July 8, 2026, Orchid Pharma executed an exclusive licensing agreement with Russian pharmaceutical major Pharmasyntez JSC for its patented hospital antibiotic Exblifep. Under the deal, Pharmasyntez holds exclusive registration and marketing rights across Russia, while Orchid retains sole manufacturing and supply mandates. Pending Russian health ministry clearance, the partnership is projected to deliver cumulative revenues of $178 million over a 10-year horizon. Final NCLT Clearance for Dhanuka Laboratories Merger In June 2026, the National Company Law Tribunal (NCLT) issued a formal order sanctioning the amalgamation of promoter entity Dhanuka Laboratories Limited into Orchid Pharma Limited. Backdated to April 1, 2024, the structural merger consolidates product portfolios and API research assets, with management targeting combined annual revenues of ₹1,400–1,500 crore and EBITDA of ₹200–250 crore. FY26 Financial Summary For the fourth quarter ended March 31, 2026 (Q4 FY26), consolidated total income grew 15.1% quarter-on-quarter to ₹244.95 crore, while net profit (PAT) recovered to ₹23.78 crore. On a full-year basis, operating EBITDA margins faced mild headwinds due to elevated raw material prices across core cephalosporin bulk drug supply chains. SEBI Compliance Window In strict compliance with SEBI LODR and Insider Trading regulations, the company executed the formal closure of its internal trading window for all designated insider groups and connected persons on June 30, 2026. The trading restriction remains fully active pending the formal board adoption and presentation of the upcoming Q1 FY27 financial results.

Ashish Kumar

8 Jul • 11:11 AM · SEBI-Registered Analyst

Orchid Pharma Shares Surge on Landmark Russia Licensing Deal for Novel Antibiotic Exblifep

ORCHPHARMA

’s shares surged nearly 9-11% after the company signed a licensing and supply agreement with Russia’s Pharmasyntez JSC for its novel antibiotic Exblifep (cefepime/enmetazobactam). Under the pact, Pharmasyntez gains exclusive rights to register and commercialize the drug in Russia for complicated urinary tract infections (cUTI) and hospital-acquired/ventilator-associated pneumonia (HAP/VAP), subject to regulatory approval. Orchid will supply the finished dosage form. The deal taps into a potential USD 178 million opportunity over 10 years, addressing rising antimicrobial resistance in Gram-negative infections. Exblifep, already approved in the US and EU, strengthens Orchid Pharma’s global footprint in the antibiotics segment.

Sumit Kadam

8 Jul • 10:18 AM · SEBI-Registered Analyst

Orchid Pharma Jumps 11% on Russia Licensing Deal

ORCHPHARMA

shares surged 11.39% to ₹1,032.15 after signing a licensing agreement with Russia's Pharmasyntez for its novel antibiotic Exblifep. Pharmasyntez gets exclusive rights to register and market Exblifep in Russia while Orchid manufactures and supplies the finished drug. The deal represents a potential $178 million revenue opportunity over 10 years. Exblifep is a novel carbapenem-sparing antibiotic a next generation drug designed to treat serious infections like complicated urinary tract infections and hospital acquired pneumonia caused by drug-resistant bacteria. It has already received approvals from both the US FDA and European Medicines Agency making it a globally validated drug now entering the Russian market. $178 million over 10 years meaningful recurring revenue for a mid-cap pharma company. Russia has large-scale hospital procurement programmes meaning Pharmasyntez can drive significant volumes through government hospital tenders rather than retail pharmacy channels. Carbapenem sparing antibiotic resistance is a global crisis. Carbapenems are last-resort antibiotics. A drug that treats serious infections without using carbapenems is medically critical commanding premium pricing and strong institutional demand worldwide. Orchid owns the drug. Pharmasyntez gets the right to sell it in Russia. Orchid manufactures and supplies. This structure gives Orchid recurring manufacturing revenue without needing to build a Russian sales team a capital efficient way to monetise innovation across geographies. Orchid Pharma's 11% rally on the Russia licensing deal taught me that novel antibiotic approvals combined with strategic licensing partnerships can unlock significant multi-year revenue streams for pharma companies, and that tracking global licensing deals alongside FDA and EMA approval pipelines is essential for identifying re-rating opportunities in specialty pharma stocks like Orchid Pharma,

CIPLA

a and

WOCKPHARMA

t before investing.

Orchid Pharma Ltd Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Orchid Pharma Ltd 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Orchid Pharma Ltd?

What is the market cap of Orchid Pharma Ltd?

Should I buy Orchid Pharma Ltd stock now?

What is the 52 week high and low of Orchid Pharma Ltd?

Is the Orchid Pharma Ltd stock good to buy?

Is Orchid Pharma Ltd a good buy for the long term?

Is Orchid Pharma Ltd overvalued or undervalued?

What is the PE and PB ratio of Orchid Pharma Ltd?